Positive results for larotrectinib against TRK-fusion cancer. 55 patients representing 17 cancer types tested positive for TRK fusion and were treated with larotrectinib. Overall response rate was 75 percent. Source 6n.
This site uses Cookies to dispense or record information with regards to your visit. By continuing to use this site you agree to the terms outlined in ourCookies used here:Privacy / Disclaimer,